The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 318-327

  Jones, T Hugh ^a,b   Saad, Farid ^c,d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c Scientific Affairs Men's Healthcare   (Germany)

^d GULF MEDICAL UNIVERSITY   (United Arab Emirates)

Author keywords

Atherosclerosis; Cardiovascular; Testosterone

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE;

ADIPOCYTE; ANGINA PECTORIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE MODEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 70549086629     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.016     Document Type: Review

References (192)

1. Rayner M., Mockford C., and Boaz A. Coronary heart disease statistics. British heart foundation statistics database (1998), British Heart Foundation Education Department, London
2. Lerner D.J., and Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111 (1986) 383-390
3. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
4. Hanefeld M., and Leonhardt W. Das metabolische Syndrom. Dtsch Gesundheitwes 36 (1981) 545-551
5. Traish A.M., Guay A., Feeley R., and Saad F. The dark side of testosterone deficiency. I. Metabolic syndrome and erectile dysfunction. J Androl 30 1 (2009) 10-22
6. Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30 (2007) 8-13
7. Lorenzo C., Serrano-Rios M., Martinez-Larrad M.T., et al. Is waist circumference an essential component of the metabolic syndrome?. Diabetes Care 30 (2007) 2141-2142
8. Zumoff B., Strain G.W., Miller L.K., et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71 (1990) 929-931
9. Pasquali R., Casimirri F., Cantobelli S., et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 40 (1991) 101-104
10. Seidell J.C., Bjorntorp P., Sjostrom L., et al. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism 39 (1990) 897-901
11. Haffner S.M., Valdez R.A., Stern M.P., et al. Obesity, body fat distribution and sex hormones in men. Int J Obesity 17 (1993) 643-649
12. Phillips G.B. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 42 (1993) 116-120
13. Abate N., Haffner S.M., Garg A., et al. Sex steroid hormones, upper body obesity and insulin resistance. J Clin Endocrinol Metab 87 (2002) 4522-4527
14. Vermeulen A., Goemaere S., and Kaufman J.M. Testosterone, body composition and aging. J Endocrinol Invest 22 (1999) 110-116
15. Wake D.J., Strand M., Rask E., et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 66 (2007) 440-446
16. Blouin K., Boivin A., and Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 108 (2008) 272-280
17. Yanase T., Fan W., Kyoya K., et al. Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 109 (2008) 254-257
18. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 24 Suppl 2 (2000) S59-63
19. Singh R., Artaza J.N., Taylor W.E., et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144 (2003) 5081-5088
20. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
21. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88 (2003) 5452-5455
22. McTernan C.L., McTernan P.G., Harte A.L., et al. Resistin, central obesity, and type 2 diabetes. Lancet 359 (2002) 46-47
23. Kapoor D., Clarke S., Stanworth R., et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156 (2007) 595-602
24. Swarbrick M.M., and Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6 (2008) 87-102
25. Lanfranco F., Zitzmann M., Simoni M., et al. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 60 (2004) 500-507
26. Haffner S.M., Karhapää P., Mykkänen L., and Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43 (1994) 212-219
27. Simon D., Charles M.A., Nahoul K., et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82 (1997) 682-685
28. Oh J.Y., Barrett-Connor E., Wedick N.M., et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women. Diabetes Care 25 (2002) 55-60
29. Stellato R.K., Feldman H.A., Hamdy O., et al. Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle aged men. Diabetes Care 23 (2000) 490-494
30. Haffner S.M., Shaten J., Stern M.P., et al. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol 143 (1996) 889-897
31. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Internal Med 117 (1992) 807-811
32. Zietz B., Schäffler A., Büttner R., Schölmerich J., and Palitzsch K.D. Elevated levels of leptin and insulin but not of TNF alpha are associated with hypertension in type 2 diabetic males. Exp Clin Endocrinol Diab 108 (2000) 259-264
33. Fukui M., Ose H., Kitagawa Y., et al. Relationship between low serum endogenous androgen concentrations and arterial stiffness in men with type 2 diabetes mellitus. Metabolism 56 (2007) 1167-1173
34. Grossmann M., Thomas M.C., Panagiotopoulos S., et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93 (2008) 1834-1840
35. Kapoor D., Aldred H., Clark S., et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30 (2007) 911-917
36. Boyanov M.A., Boneva Z., and Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6 (2003) 1-7
37. Kapoor D., Goodwin E., Channer K.S., et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154 (2006) 899-906
38. Marin P., Oden B., and Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80 (1995) 239-243
39. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 (2004) 447-452
40. Pitteloud N., Mootha V.K., Dwyer A.A., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28 7 (2005) 1636-1642
41. Cohen P.G. The hypogonadal-obesity cycle. Med Hypotheses 52 (1999) 49-51
42. Yialamas M.A., Dwyer A.A., Hanley E., et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92 (2007) 4254-4259
43. Chubb S.A., Hyde Z., Almeida O.P., et al. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol 158 (2008) 785-792
44. Maron D.J. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 86 (2000) 11-14
45. Simons L.A., McCallum J., Friedlander Y., et al. Risk factors for ischemic stroke: Dubbo Study of the elderly. Stroke 29 (1998) 1341-1346
46. Hickey J.T., Hickey L., Yancy W.S., et al. Clinical use of a carbohydrate-restricted diet to treat the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 1 (2003) 227-232
47. Adiels M., Olofsson S.O., Taskinen M.R., et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008) 1225-1236
48. Traish A.M., Saad F., and Guay A. The dark side of testosterone deficiency. II. Type 2 diabetes & insulin resistance. J Androl 30 1 (2009) 23-32
49. Barrett-Connor E., and Khaw K.T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78 (1988) 539-545
50. Haffner S.M., Mykkanen L., Valdez R.A., et al. Relationship of sex hormones to lipids anf lipoproteins in non-diabetic men. J Clin Endocrinol Metab 77 (1993) 1610-1615
51. Barud W., Palusinski R., Beltowski J., et al. Inverse relationship between total testosterone and anti-oxidised low density lipoprotein antibody levels in aging males. Atherosclerosis 164 (2002) 283-288
52. Malkin C.J., Pugh P.J., Morris P.D., et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90 (2004) 871-876
53. Fan A.Z., and Dwyer J.H. Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: the Los Angeles Atherosclerosis Study. Atherosclerosis 195 (2007) e191-e196
54. Johnsen S.H., Mathiesen E.B., Fosse E., et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø study. Circulation 112 (2005) 498-504
55. Van Pottelbergh I., Braeckman L., De Bacquer D., et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166 (2003) 95-102
56. Stanworth R.D., Kapoor D., Channer K.S., et al. Testosterone levels correlate positively with HDL cholesterol levels in men with type 2 diabetes. Endocr Abstr 14 (2007) P628
57. Cohen P.G. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 70 (2008) 358-360
58. Cohen P.G. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 56 (2001) 702-708
59. Yasui T., Uemura H., Irahara M., et al. Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women. Clin Chim Acta 398 (2008) 43-47
60. Tomaszewski M, Charchar FJ, Maric C, et al. Association between lipid profile and circulating concentrations of estrogens in young men. Atherosclerosis. 2008; June 17 [Epub ahead of print].
61. Vaidya D., Dobs A., Gapstur S.M., et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism 57 (2008) 782-790
62. Nettleship J.E., Pugh P.J., Channer K.S., et al. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 39 (2007) 366-371
63. Svartberg J., von Muehlen D., Schirmer H., et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø study. Eur J Endocrinol 150 (2004) 65-71
64. Khaw K.T., and Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 6 (1988) 329-332
65. Messerli F.H., Garavaglia G.E., Schmieder R.E., et al. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med 107 (1987) 158-161
66. Bocchi E.A., Carvalho V.O., and Guimaraes G.V. Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Int Braz J Urol 34 (2008) 302-310
67. Maravelias C., Dona A., Stefanidou M., et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett 158 (2005) 167-175
68. Mottram D.R., and George A.J. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2000) 55-69
69. Sullivan M.L., Martinez C.M., Gennis P., et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41 (1998) 1-15
70. Marin P., Holmang S., Gustafsson C., et al. Androgen treatment of abdominally obese men. Obesity Res 1 (1993) 245-251
71. Andersen F.H., Francis R.M., and Faulkner K.F. Androgen supplementation in eugonadal men with osteoporosis effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18 (1996) 171-177
72. Zitzmann M., and Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92 (2007) 3844-3853
73. Carneiro F.S., Sturgis L.C., Giachini F.R.C., et al. TNF-a knockout mice have increased corpora cavernosa relaxation. J Sex Med 6 (2009) 115-125
74. Hatakeyama H., Nishizawa M., Nakagawa A., et al. Testosterone inhibits tumor necrosis factor-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 530 (2002) 129-132
75. D'Agostino P., Milano S., Barbera C., et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 876 (1999) 426-429
76. Gornstein R.A., Lapp C.A., Bustos-Valdes S.M., et al. Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. J Periodontol 70 (1999) 604-609
77. Hofbauer L.C., Ten R.M., and Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 14 (1999) 1330-1337
78. Li Z.G., Danis V.A., and Brooks P.M. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheumatol 11 (1993) 157-162
79. Bellido T., Jilka R.L., Boyce B.F., et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 95 (1995) 2886-2895
80. Liva S.M., and Voskuhl R.R. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol 167 (2001) 2060-2067
81. Corrales J.J., Almeida M., Burgo R., et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189 (2006) 595-604
82. Musabak U., Bolu E., Ozata M., et al. Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism. Clin Exp Immunol 132 (2003) 265-270
83. Malkin C.J., Pugh P.J., Jones R.D., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 3313-3318
84. Zitzmann M., Erren M., Kamischke A., et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 90 (2005) 6603-6608
85. Guler N., Batyraliev T., Dulger H., et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol 109 (2006) 339-343
86. Ridker P. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49 (2007) 2129-2138
87. Ben-Yehuda O. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients. J Am Coll Cardiol 49 (2007) 2139-2141
88. Ridker P.M., and Silvertown J.D. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 79 (2008) 1544-1551
89. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 21 (2008) 2195-2207
90. Yang Y.M., Lv X.Y., Huang W.D., et al. Study of androgen and atherosclerosis in old age male. J Zhejiang Univ Sci B6 (2005) 931-935
91. Bhatia V., Chaudhuri A., Tomar R., et al. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29 (2006) 2289-2294
92. Ng M.K., Liu P.Y., Williams A.J., et al. Prospective study of effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 22 (2002) 1136-1141
93. Singh A.B., Hsia S., Alaupovic P., et al. The effects of varying doses of testosterone on insulin sensitivity, plasma lipids, apolipoproteins and C-reactive protein in healthy young men. J Clin Endocrinol Metabol 87 (2002) 136-143
94. Haidar A., Yassin A., Saad F., et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 (2007) 189-196
95. Lesser M.A. Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol 6 (1946) 549-557
96. Malkin C.J., Pugh P.J., West J.N., et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27 (2006) 57-64
97. Pugh P.J., Jones T.H., and Channer K.S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24 (2003) 909-915
98. Pugh P.J., Malkin C.J., Morris P.D., et al. Prevalence of hypogonadism in men with coronary artery disease. J Am Coll Cardiol 41 (2003) 344A
99. Rosano G.M., Sheiban I., Massaro R., et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19 (2007) 176-182
100. Corona G., Mannucci E., Lotti M.D., et al. Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with erectile dysfunction. J Sex Med 6 (2009) 285-293
101. Corona G., Mannucci E., Fisher A.D., et al. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 5 (2008) 2454-2463
102. Kang S.M., Jang Y., Kim J.Y., et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89 (2002) 862-864
103. Webb C.M., Mc Neill J.G., Hayward C.S., De Zeigler D., and Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100 (1999) 1690-1696
104. Jones R.D., Pugh P.J., Jones T.H., et al. The vasodilatory action of testosterone: a potassium-channel opening or calcium antagonistic action?. Br J Pharmacol 138 (2003) 733-744
105. Yue P., Chatterjee K., Beale C., et al. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91 (1995) 1154-1160
106. Chou T.M., Sudhir K., Hutchison S.J., et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94 (1996) 2614-2619
107. Deenadayalu V.P., White R.E., Stallone J.N., et al. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281 (2001) H1720-H1727
108. Cairrão E., Alvarez E., Santos-Silva A.J., et al. Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn Schmiedebergs Arch Pharmacol 376 (2008) 375-383
109. English K.M., Jones R.D., Jones T.H., et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 5 (2002) 455-458
110. 2+ channels. Biochem Biophys Res Commun 318 (2004) 503-506
111. Hall J., Jones R.D., Jones T.H., et al. Selective inhibition of L-type voltage-gated calcium channels in A7r5 cells by physiological levels of testosterone. Endocrinology 147 (2006) 2675-2680
112. Perusquía M., Navarrete E., González L., et al. The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci 81 (2007) 993-1002
113. Lafayette S.S., Vladimirova I., Garcez-do-Carmo L., et al. Evidence for the participation of calcium in non-genomic relaxations induced by androgenic steroids in rat vas deferens. Br J Pharmacol 153 (2008) 1242-1250
114. Ding A.Q., and Stallone J.N. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 91 (2001) 2742-2750
115. Tep-areenan P., Kendall D.A., and Randall M.D. Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135 (2002) 735-740
116. Ebenbichler C.F., Sturm W., Gänzer H., et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158 (2001) 483-490
117. Lane H.A., Grace F., Smith J.C., et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest 36 (2006) 483-488
118. Kanayama G., Hudson J.I., and Pope Jr. H.G. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend 98 (2008) 1-12
119. Iliescu R., and Reckelhoff J.F. Testosterone and vascular reactivity. Clin Sci (Lond) 11 (2006) 251-252
120. Bernini G., Versari D., Moretti A., et al. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab 91 (2006) 1691-1697
121. Zitzmann M., Brune M., and Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 87 (2002) 5030-5037
122. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
123. Heiss C., Keymel S., Niesler U., et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 45 (2005) 1441-1448
124. Hoetzer G.L., Van Guilder G.P., Irmiger H.M., et al. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. J Appl Physiol 102 (2007) 847-852
125. Keymel S., Kalka C., Rassaf T., et al. Impaired endothelial progenitor cell function predicts age-dependent carotid intimal thickening. Basic Res Cardiol 103 6 (2008) 582-586
126. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 1 (2001) E1-7
127. Foresta C., Caretta N., Lana A., et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 91 (2006) 4599-4602
128. Foresta C., Zuccarello D., De Toni L., et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf) 68 (2008) 284-289
129. Pearson L.J., Yandle T.G., Nicholls M.G., et al. Regulation of endothelin-1 release from human endothelial cells by sex steroids and angiotensin-II. Peptides 29 (2008) 1057-1061
130. Kumanov P., Tomova A., Kirilov G., et al. Increased plasma endothelin levels in patients with male hypogonadism. Andrologia 34 (2002) 29-33
131. Kumanov P., Tomova A., and Kirilov G. Testosterone replacement therapy in male hypogonadism is not associated with increase of endothelin-1 levels. Int J Androl 30 (2007) 41-47
132. Phillips G.B., Pinkernell B.H., and Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14 (1994) 701-706
133. Glueck C.J., Glueck H.I., Stroop D., et al. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 122 (1993) 412-420
134. Pugh P.J., Channer K.S., Parry H., et al. Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res 28 (2002) 161-173
135. Smith A.M., English K.M., Malkin C.M., et al. Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 152 (2005) 285-291
136. Beer N.A., Jakubowicz D.J., Matt D.W., et al. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci 311 (1996) 205-210
137. Caron P., Bennet A., Camare R., et al. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabol Clin Exp 38 (1989) 1010-1015
138. Muller M., van den Beld A.W., Bots M.L., et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109 (2004) 2074-2079
139. Svartberg J., von Mühlen D., Mathiesen E., et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 259 (2006) 576-582
140. Makinen J., Jarvisalo M.J., Pöllanen P., et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45 (2005) 1603-1608
141. Demirbag R., Yilmaz R., Ulucay A., et al. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res 31 (2005) 335-344
142. Fukui M., Kitagawa Y., Nakamura N., et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 26 (2003) 1869-1873
143. Zitzmann M., Vorona E., Wenk M., et al. Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle-aged overweight men. J Androl 29 Suppl. (2008) 54-55
144. Larsen B.A., Nordestgaard B.G., Stender S., et al. Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99 (1993) 79-86
145. Alexandersen P., Haarbo J., Byrjalsen I., et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 84 (1999) 813-819
146. Bruck B., Brehme U., Gugel N., et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17 (1997) 2192-2199
147. Nathan L., Shi W.B., Dinh H., et al. Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase. Proc Nat Acad Sci USA 98 (2001) 3589-3593
148. Nettleship J.E., Channer K.S., Jones T.H., and Jones R.D. Physiological testosterone replacement therapy attenuates fatty streak formation and improves HDL-C in the Tfm mouse: an effect which is independent of the classical androgen receptor. Circulation 116 21 (2007) 2427-2434
149. Jones R.D., Nettleship J.E., Kapoor D., et al. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 5 (2005) 141-154
150. Tsang S., Liu J., and Wong T.M. Testosterone and cardioprotection against myocardial ischemia. Cardiovasc Hematol Disord Drug Targets 7 (2007) 119-125
151. Tsang S., Wu S., Liu J., et al. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol 153 (2008) 693-709
152. Crisostomo P.R., Wang M., Wairiuko G.M., et al. Brief exposure to exogenous testosterone increases death signaling and adversely affects myocardial function after ischemia. Am J Physiol Regul Integr Comp Physiol 290 (2006) R1168-R1174
153. Wang M., Tsai B.M., Kher A., et al. Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol 288 (2005) H221-H226
154. Mohammed A.A., Thwaini A., Shergill I.S., et al. Hypoandrogen-metabolic syndrome: a significant issue for men's health. BJU Int 98 (2006) 1329
155. Hougaku H., Fleg J.L., Najjar S.S., et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 290 (2006) E234-E242
156. Dockery F., Bulpitt C.J., Donaldson M., et al. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc 51 (2003) 1627-1632
157. Smith G.D., Ben-Shlomo Y., Beswick A., et al. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112 (2005) 332-340
158. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
159. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
160. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
161. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
162. Bebo Jr. B.F., Schuster J.C., Vandenbark A.A., et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol 162 (1991) 35-40
163. Jones T.H. Testosterone associations with erectile dysfunction, diabetes and metabolic syndrome. Eur Urol Suppl 6 (2007) 847-857
164. World Health Organization fact sheet No. 317, February 2007. http://www.who.int/mediacentre/factsheets/fs317/en/print.html, accessed 26 September 2008.
165. Rebuffe-Scrive M., Marin P., and Bjorntrop P. Effect of testosterone on abdominal adipose tissue in men. Int J Obesity 15 (1991) 791-795
166. Tenover J.S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metabol 75 (1992) 1092-1098
167. Marin P. Testosterone and regional fat distribution. Obes Res 3 (1995) 609S-612S
168. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metabol 84 (1999) 2647-2653
169. Kenny A.M., Prestwood K.M., Gruman C.A., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Biol Sci Med Sci 56 (2001) M266-M273
170. Simon D., Charles M.A., Lahlou N., et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care 24 (2001) 2149-2151
171. Naharci M.I., Pinar M., Bolu E., et al. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 13 (2007) 629-635
172. Saad F., Gooren L., Haider A., et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 53 (2007) 353-357
173. Saad F., Gooren L.J., Haider A., et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29 1 (2008) 102-105
174. Agledahl I., Hansen J.B., and Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest 11 (2008) 1-8
175. Allan C.A., Strauss B.J.G., Burger H.G., et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93 (2008) 139-146
176. Jones H., Behre H., Channer K., and Volterrani M. An international study of testosterone (T) gel in hypogonadal men with type II diabetes (T2D) and/or metabolic syndrome (METS, IDF criteria): The TIMES2 study. J Diabetes 1 suppl 1 (2009) pA37
177. Thompson P.D., Cullinane E.M., Sady S.P., et al. Contrasting effects of
178. Bagatell C.J., Heiman J.R., Matsumoto A.M., et al. Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab 79 (1994) 561-567
179. Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121 (1996) 35-43
180. Uyanik B.S., Ari Z., Gumus B., et al. Beneficial Effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J 38 (1997) 73-82
181. Tripathy D., Shah P., Lakshmy R., et al. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotropic hypogonadism. Hormone Metabolic Res 30 (1998) 642-645
182. Howell S.J., Radford J.A., Adams J.E., et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol 55 (2001) 315-324
183. Ly L.P., Jimenez M., Zhuang T.N., et al. A double-blind, placebo-controled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86 (2001) 4078-4088
184. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol 2 (1942) 325-328
185. Walker T.C. The use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol 2 (1942) 560-568
186. Levine S.A., and Likoff W.B. The therapeutic value of testosterone propionate in angina pectoris. N Engl J Med 229 (1943) 770-772
187. Sigler L.H., and Tulgan J. Treatment of angina pectoris by testosterone. NY State J Med 43 (1943) 1424-1428
188. Jaffe M.D. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 9 (1977) 1217-1222
189. Wu S.Z., and Weng X.Z. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 106 (1993) 415-418
190. Rosano G.M., Leonardo F., Pagnotta P., et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99 (1999) 1666-1670
191. Webb C.M., Adamson D.L., de Zeigler D., et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83 (1999) p. 437-9, A9
192. English K.M., Steeds R.P., Jones T.H., et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102 (2000) 1906-1911